# Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

> **NCT04369183** · — · COMPLETED · sponsor: **Istanbul University** · enrollment: 25 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis
- Minimal Change Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04369183
- **Lead sponsor:** Istanbul University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04369183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04369183, "Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04369183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*